mitigating cardiological toxicities associated with btki in b-cell malignancies
Published 5 months ago • 49 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
2:39
managing the potential cardiotoxicity associated with btkis: important considerations
-
1:55
cardiac toxicities associated with btk inhibitor treatment
-
4:25
tg-1701: a btk inhibitor for b-cell malignancies
-
1:45
the value of teclistamab in r/r myeloma & strategies to mitigate toxicities
-
2:52
acquired mutations associated with resistance to btki in patients with cll
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:28
risk factors associated with ta-tma in patients with gvhd
-
2:46
overview of bruton's tyrosine kinase (btk) inhibitors in chronic lymphocytic leukemia
-
8:36
thrombotic microangiopathy - ttp and hus
-
1:29:55
thrombotic microangiopathy part 1:dr.noha gamal
-
53:11
glyco-checkpoints as therapeutic targets in cancer, autoimmunity & infection by dr. g. rabinovich
-
2:33
btki resistance and it's management
-
2:33
the effect of lymphodepleting agents on rate and severity of toxicities following car-t infusion
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
0:45
cys-ser mutation-driven ibrutinib resistance and alternative btki’s under development
-
6:11
first-in-human study of the menin-kmt2a inhibitor jnj-75276617 in r/r acute leukemias
-
0:52
monitoring, diagnosing & managing cardiotoxicity in al amyloidosis
-
2:15
cardiac biomarkers for immune checkpoint inhibitor-related myocarditis in cancer patients
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
1:32
factors contributing to the pathogenesis of icaht
-
0:45
difference between quality of life & patient-reported outcomes
-
1:09
emerging treatment options for refractory immune thrombocytopenia